News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

May 1997

Clinical Considerations in GERD Therapy: Focus on Cisapride

ByWilliam J. Snape, Jr., MD

May 1st 1997

Improving the Quality of the NCQA Annual Member Health Care Survey Version 1.0

ByLaura Sue Kippen, ABD,Stephen Strasser, PhD,Maulik Joshi, MHSA

May 1st 1997

The Diagnostic and Treatment Approach to Two Common Conditions by the Physician Members of a Community Health Maintenance Organization

ByBernard S. Bloom, PhD,William P. Smith, RPh,David Weitz,Bruce Lamont, MS, MBA

May 1st 1997

Economic Winners and Losers After Introduction of an Effective New Therapy Depend on the Type of Payment System

ByWilliam S. Weintraub, MD,Christi D. Warner, PhD,Patrick D. Mauldin, PhD,Edmund R. Becker, PhD,Daniel Gomes, MPH,John Cook, PhD,Andrzej

May 1st 1997

Health Outcomes and Managed Care: Discussing the Hidden Issues

ByMarshall H. Chin, MD, MPH

May 1st 1997

Resource Utilization and Work or School Loss Reported by Patients with Diabetes: Experience in Diabetes Training Programs

ByJohn C. Licciardone, DO, MBA,James G. Kotsanos, MD, MS,Valerie Brinkman-Kaplan, MS, RD, CDE,Tamara Cooper, RN, CDE,Jack E. Jordan, MBA,Kathleen L

May 1st 1997

Diagnosis and Treatment of Chronic Renal Failure in Children

ByHoward Trachtman, MD

May 1st 1997

Competency, Board Certification, Credentialing, and Specialization: Who Benefits?

ByDick R. Gourley, PharmD,Walter L. Fitzgerald, Jr., Pharm, MS, JD,Roger L. Davis, PharmD

May 1st 1997

Correspondence regarding, "Appropriate and Necessary Healthcare: New Language for a New Era"

ByEdmund Pellegrino, MD,Author reply from Charles N. Oberg, MD,Marilyn L. Bach, PhD

May 1st 1997

Trending on AJMC

Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic

5 Things to Know About Diabetes-Related Eye Disease Awareness Month

No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations

Phase 3 Trial Tests Ensifentrine for COPD Exacerbation Prevention

FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC